By otakuyassine3@gmail.com 
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price reduced by Chardan Capital from $94.00 to $84.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.
Several other equities research analysts have also recently commented on CRSP. Royal Bank of Canada cut their price objective on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research report on Wednesday. HC Wainwright restated a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a report on Thursday. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. JMP Securities reaffirmed a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Finally, Barclays boosted their price objective on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and an average price target of $74.50.
Read Our Latest Stock Report on CRISPR Therapeutics
CRISPR Therapeutics Price Performance
Shares of CRISPR Therapeutics stock opened at $49.72 on Thursday. CRISPR Therapeutics has a 1 year low of $36.52 and a 1 year high of $91.10. The company has a market capitalization of $4.24 billion, a P/E ratio of -17.57 and a beta of 1.67. The business has a 50-day moving average of $41.89 and a two-hundred day moving average of $46.10.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. On average, equities analysts anticipate that CRISPR Therapeutics will post -5.08 EPS for the current fiscal year.
Insider Activity
In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at $10,002,854. This trade represents a 7.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the stock. Boston Family Office LLC increased its stake in shares of CRISPR Therapeutics by 2.2% in the 3rd quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock valued at $459,000 after purchasing an additional 213 shares during the last quarter. Bedell Frazier Investment Counselling LLC lifted its holdings in shares of CRISPR Therapeutics by 0.8% in the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock worth $1,238,000 after acquiring an additional 218 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of CRISPR Therapeutics by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock worth $586,000 after acquiring an additional 231 shares during the last quarter. Intellectus Partners LLC grew its holdings in shares of CRISPR Therapeutics by 3.6% during the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock valued at $281,000 after purchasing an additional 250 shares during the last quarter. Finally, Farrow Financial Inc. grew its holdings in shares of CRISPR Therapeutics by 1.4% during the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock valued at $777,000 after purchasing an additional 270 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Featured Stories
Receive News & Ratings for CRISPR Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRISPR Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.